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Abstract: Background: With the emergence and spread of new SARS-CoV-2 variants, concerns
are raised about the effectiveness of the existing vaccines to protect against these new variants.
Although many vaccines were found to be highly effective against the reference COVID-19 strain,
the same level of protection may not be found against mutation strains. The objective of this study
is to systematically review relevant studies in the literature and compare the efficacy of COVID-19
vaccines against new variants. Methods: We conducted a systematic review of research published
in Scopus, PubMed, and Google Scholar until 30 August 2021. Studies including clinical trials,
prospective cohorts, retrospective cohorts, and test negative case-controls that reported vaccine
effectiveness against any COVID-19 variants were considered. PRISMA recommendations were
adopted for screening, eligibility, and inclusion. Results: 129 unique studies were reviewed by the
search criteria, of which 35 met the inclusion criteria. These comprised of 13 test negative case-control
studies, 6 Phase 1–3 clinical trials, and 16 observational studies. The study location, type, vaccines
used, variants considered, and reported efficacies were highlighted. Conclusion: Full vaccination
(two doses) offers strong protection against Alpha (B.1.1.7) with 13 out of 15 studies reporting more
than 84% efficacy. The results are not conclusive against the Beta (B.1.351) variant for fully vaccinated
individuals with 4 out of 7 studies reporting efficacies between 22 and 60% and 3 out of 7 studies
reporting efficacies between 75 and 100%. Protection against Gamma (P.1) variant was lower than
50% according to two studies in fully vaccinated individuals. The data on Delta (B.1.617.2) variant is
limited but indicates lower protection compared to other variants.
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1. Introduction
As of 31 August 2021, 217 million infections and more than 4.5 million deaths [1]
have been attributed to SARS-CoV-2, commonly referred to as the COVID-19 pandemic.
The worldwide impacts on sectors including the economy [2] and public health [3] were
catastrophic due to public restrictions and lockdown. A potential solution for ending
the pandemic was introduced by the emergence of safe and effective vaccines [4]. Early
clinical trials for many vaccines were reported to be highly effective against the reference
SARS-CoV-2 variant [4,5] and more than 5 billion vaccine doses have been administered
by 31 August 2021 [1]. However, once new variants of the virus were discovered in the
population, there has been a growing concern regarding the level of protection ensured
by vaccines. A mathematical modeling demonstrated the possibility of acquiring a high
level of immunity in the population if the vaccine efficacy is maintained across the different
strains [6]. The level of vaccine efficacy required to reach a communal level of protection
poses a challenging question. According to computational modeling and simulation
experiments, a minimum of 60% vaccine efficacy is required to end an ongoing epidemic if
the vaccination coverage is 100% [7]. However, given that a 100% vaccine coverage is highly
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2.3. Risk of Bias Assessment
The included studies were evaluated using the risk of bias in the prevalence tool with
a resulting estimate in line with Cochrane GRADE criteria of low, moderate, or high risk of
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bias [15]. A series of 10 questions related to the sampling and data collection of the studies
were answered using this tool. Each question is answered with a yes/no response and a
lack of information is assumed to be unclear/no. The final score is a sum of all negative
answers and scores of 0–3 are considered low risk, 4–6 are moderate risk, and 7–10 are
high risk.
3. Results
The characteristics of the included studies are summarized next. Out of the 35 included
studies, 20 (57%) were peer-reviewed and 15 (43%) were preprints or reports. The Delta
(B.1.617.2) variant was the latest variant to be declared a variant of concern (VOC) by
Public Health England on 6th May 2021 [9]. Therefore, the majority (70%) of the studies
reporting efficacy against the Delta variant were not peer-reviewed at the time of writing
this paper. However, these research works are still expected to provide an early indication
of the vaccine efficacy against the Delta variant. In terms of location, eight studies were
from the United Kingdom (UK), seven from the United States (US), five from South Africa,
four from Canada, three from Qatar, two each from France and Brazil, one each from Italy,
India, Israel, and Europe.
According to the risk of bias tool for assessing the included studies, three of the studies
were considered to be at a high risk of bias, 15 were considered to be at a moderate risk
of bias, and 17 were considered to be at a low risk of bias. The results are summarized in
Table 1, and the full scoring details are provided in the Supplementary Materials.
Table 1. Risk of Bias Assessment.
Study
P. T. Heath et al. [16]
K. R. W. Emary et al. [17]
E. Mahase [18]
L. J. Abu-Raddad et al. [19]
H. Chemaitelly et al. [20]
J. Lopez Bernal et al. [21]
A. Puranik et al. [22]
R. Duerr et al. [23]
M. W. Tenforde et al. [24]
J. Lopez Bernal et al. [25]
E. J. Haas et al. [26]
V. J. Hall et al. [27]
M. E. Flacco et al. [28]
M. Shrotri et al. [29]
V. J. Hall et al. [30]
E. Kissling et al. [31]
T. Charmet et al. [32]
H. Chung et al. [33]
A. Yassi et al. [34]
D. M. Skowronski et al. [35]
S. Nasreen et al. [36]
V. Shinde et al. [37]
J. Sadoff et al. [38]
S. J. Thomas et al. [39]
O. T. Ranzani et al. [40]
M. D. T. Hitchings et al. [41]
S. A. Madhi et al. [42]
B. Lefèvre et al. [43]
R. Herlihy et al. [44]
S. Y. Tartof et al. [45]
A. Fowlkes et al. [46]
P. Tang et al. [47]
X.-N. Li et al. [48]
R. Thiruvengadam et al. [49]
L. T. Keegan et al. [50]

Overall Risk of Bias
Low
Low
High
Moderate
Low
Low
Low
Moderate
Moderate
Low
Low
Moderate
Moderate
Low
Moderate
Moderate
Moderate
Moderate
Moderate
Low
Low
Low
Low
Low
Low
Moderate
Low
Moderate
High
Low
Moderate
Moderate
Low
Moderate
High

The following subsections discusses the vaccine effectiveness and provides a comparison against the newer variants.

Vaccines 2021, 9, 1305

5 of 18

3.1. Vaccine Protection against Alpha (B.1.1.7) SARS-CoV-2 Variant
Given that B.1.1.7 was the earliest variant to be designated a VOC, more data of
vaccine efficacy is available for this variant than any other. A total of 21 of the 35 (60%)
studies reported vaccine efficacy against this variant, as summarized in Table 2.
Several articles reported efficacies from Phase 2 and 3 clinical trials ([16–18]). The
efficacies range from 70.4% and 85.6% against B.1.1.7 for AstraZeneca and Novavax vaccines. The Novavax Phase 3 trial was conducted between 28 September and 28 November
2020, on 16,645 adults aged between 18 and 84 years in the UK [16]. A Post hoc analysis
showed that the efficacy against the Alpha (B.1.1.7) variant was lower than the non-B.1.1.7
variants, the majority of which are likely to be the reference strain given the study period.
The efficacy against the Alpha variant was 86% whereas the efficacy against the non-Alpha
variants were higher at 96.4%. The results from this clinical trial are further confirmed by
E. Mahase [18]. A Phase 2 trial for the AstraZeneca vaccine [17] with 8534 adults aged 18
or older from 31 May and 13 November 2020, in the UK also confirmed a lower efficacy
for B.1.1.7 through post hoc analysis. A vaccine efficacy of 70.4% was reported against the
Alpha variant whereas the efficacy was higher at 81.5% for non-Alpha variants.
From the observational studies, a wider range of efficacies are reported. The efficacy of
a single dose vaccine was reported to be as low as 29.5% for BNT162b (Pfizer–BioNTech) [19]
and as high as 88.1% for mRNA-1273 (Moderna) [20]. Similar variability is observed for two
doses of vaccines where the lowest efficacy reported was 74.5% for two doses of ChAdOx1
nCoV-19 (AstraZeneca) vaccine [21] and the highest efficacy of 100% for mRNA-1273
(Moderna) [20]. Efficacy of 50% or greater is substantial and would offer useful herd
immunity [8]. Overall, the results in Table 2 indicate that two doses of any reported
vaccines provide good protection against B.1.1.7. Full vaccination (two doses) offers strong
protection against Alpha with 13 out of 15 studies reporting more than 84% efficacy and a
single dose offers reasonable protection with 10 out of 12 studies reporting greater than
54% efficacy. Moreover, the efficacies reported by the mRNA vaccines (BNT162b and
mRNA-1273) appear to be slightly higher comparatively. Furthermore, protection against
B.1.1.7 is estimated to be higher than B.1.617.2 [22]. An analysis of 76 breakthrough cases
after full vaccination in metropolitan New York was presented by R. Duerr et al. [23]. It was
observed that 4 of the 7 hospitalized cases were infected with the Alpha variant, including
1 death. The study also reported that the vaccines offer strong protection against B.1.1.7
statistically but the level of efficacy was not quantified.
3.2. Vaccine Protection against Beta (B.1.351) and Gamma (P.1) SARS-CoV-2 Variant
Both E484K-positive mutations, B.1.351 (E484K and K417N) and P.1 (E484K and
K417T) were reported together in several studies. The results against these two variants
are summarized in Table 3.
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Table 2. Vaccine Effectiveness Against Alpha (B.1.1.7) Variant.
Reference

Study Type

Population and Period

Location

[16]

Phase 3, randomized,
observer-blinded,
placebo-controlled trial

15,187
participants aged 18–84.
28 September–28 November 2020

UK

[17]

Single-blind,
randomized Phase 2
trial

8534 participants aged ≥18.
31 May–13 November 2020

UK

[18]

Phase 2 and Phase 3
trials

N/A

UK

[19]

Test negative
case-control study

Qatari resident. February-March, 2021

Qatar

[20]

Test negative
case-control study

50,068 PCR-confirmed and negative for
B.1.1.7 Qatari residents. 28 December
2020–10 May 2021

Qatar

[21]

Test negative
case-control study

19,109 participants aged ≥16. 26 October
2020–30 May 2021

UK

[22]

Test negative
case-control study

25,589 participants aged ≥18.
January–July 2021

US

[23]

Observational study

126,367 fully vaccinated individuals.
February–April 2021

[24]

Observational
case-control study

1210 hospitalized adults aged ≥18. 11
March–5 May 2021

Vaccine +

Reported Vaccine Efficacy

NVX-CoV2373

86.3% (95% CI 71.3–93.5) against B.1.1.7 and 96.4% (73.8–99.5)
against non-B.1.1.7 variants

ChAdOx1 nCoV-19

70.4% (95% CI 43.6–84.5) against B.1.1.7 and 81.5% (67.9–89.4)
against non-B.1.1.7 variants

NVX-CoV2373

85.6% (CI Not reported) *

BNT162b2

Single dose: 29.5% (95% CI 22.9–35.5)
Double dose: 89.5% (85.9–92.3) ≥14 days after the second dose

mRNA-1273

Single dose: 88.1% (95% CI 83.7–91.5) ≥14 days after first dose
Double dose: 100% (91.8–100.0) ≥14 days after the second dose

BNT162b2,
ChAdOx1 nCoV-19

BNT162b2 and ChAdOx1 nCoV-19 Single dose: 48.7%
(95% CI, 45.5–51.7).
BNT162b2 Double dose: 93.7% (91.6–95.3)
ChAdOx1 nCoV-19 Double dose: 74.5% (68.4–79.4)

X

BNT162b2, mRNA-1273

Results aggregated against all variants *:
mRNA-1273: 86% (95% CI 81–90.6) *; BNT162b2: 76% (69–81)
≥14 days after the second dose. Effectiveness against B.1.1.7
was estimated to be higher than B.1.617.2

US

X

BNT162b2, mRNA-1273

High efficacy in fully vaccinated individuals. Did not quantify.

US

X

BNT162b2 and mRNA-1273

BNT162b2: 84.3% (95% CI 74.6–90.3) *
mRNA-1273 90.0% (82.0–94.4). Both Double doses

BNT162b2,
ChAdOx1 nCoV-19

BNT162b2 Single dose: 61% (95% CI 51–69) * from 28 to 34 days
after vaccination and then plateaued, Double dose: 89% (85–93)
after 14 days from the second dose.
ChAdOx1 nCoV-19 Single dose: 60% (41–73) from 28 to 34 days,
increasing to 73% (27–90) from day 35

BNT162b2

95.3% (95% CI 94·9–95·7) * from 7 days or longer after the
second dose

BNT162b2

Single dose: 70% (95% CI 55–85) * 21 days after the first dose
Double dose: 85% (74–96) 7 days after two doses

[25]

Test negative
case-control study

156,930 adults aged ≥70. 8 December
2020–19 February 2021

UK

[26]

Observational study

Residents of Israel aged ≥16.
24 January–3 April 2021

Israel

[27]

Prospective cohort
study

23,324 hospital staff aged ≥18. 7
December 2020–5 February 2021

UK

Peer-Reviewed

√

√

X

√
√

√

√

√
√
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Table 2. Cont.
Reference

Study Type

Population and Period

Location

[28]

Retrospective cohort
study

245,226 Pescara resident aged ≥18.
2 January 2021–21 May 2021

Italy

[29]

Prospective cohort
study

10,412 care home residents aged ≥65.
8 December 2020–15 March 2021

UK

[30]

Prospective cohort
study

23,324
staff working in hospitals.
8 December 2020–5 February 2021

UK

[31]

Test negative
case-control study

4964 patients aged ≥65.
10 December 2020–31 May 2021

Europe

[32]

Case-control study
(Questionnaire-based)

41,151 questionnaire respondants and
3644 controls. 14 February–3 May 2021

France

[33]

Test negative
case-control study

324,033 residents aged ≥16. 14
December 2020–19 April 2021

Canada

[34]

Observational study

25,558 health care workers aged 20–69.
15 March 2020–13 May 2021

Canada

[35]

Test negative
case-control study

16,993 participants aged ≥70.
4 April–1 May 2021

Canada

[36]

Test negative
case-control study

682,071 symptomatic individuals aged
≥16. December 2020–March 2021

Canada

Peer-Reviewed

Vaccine +

Reported Vaccine Efficacy

√

BNT162b2,
ChAdOx1 nCoV-19,
mRNA-1273

BNT162b2 Single dose: 55% (95% CI 0.34–0.60) *, Double dose:
98% (0.01–0.04)
ChAdOx1 nCoV-19 Single dose: 95% (0.03–0.08)
mRNA-1273 S Single dose: 93% (0.02–0.26)

√

BNT162b2, ChAdOx1
nCoV-19

56% (95% CI 19–76) at 28 to 34 days and 62% (23–81) * at 35 to
48 days after a single dose of ChAdOx1 or BNT162b2

X

BNT162b2

Single dose: 72% (95% CI 58–86) * 21 days after the first dose
Double dose: 86% (76–97) 7 days after two doses

√

BNT162b2,
ChAdOx1 nCoV-19

BNT162b2 Single dose: 61% (95% CI 39–75) *, Double dose:
87% (74–93)
ChAdOx1 nCoV-19 Single dose: 68% (39–83)

BNT162b2, mRNA-1273

Double dose: 86% (95% CI 81–90) 7 days after second dose.
Reported efficacy for both mRNA vaccines aggregated

BNT162b2, mRNA-1273

Single dose: 61% (95% CI 56–66) ≥14 days after the first dose
Double dose: 90% (85–94) ≥7 days after the second dose (for
both vaccines aggregated)
Double dose against all variants combined: BNT162b2: 91%
(88–93), mRNA-1273: 94% (86–97)

BNT162b2, mRNA-1273

Results aggregated against all variants *:
Compared with community infection rates (for both vaccines
aggregated): Single dose: 54.7% (95% CI 44.8–62.9); Double
dose: 84.8% (75.2–90.7)

BNT162b2, mRNA-1273

Single dose: 67% (95% CI 57–75) (for both vaccines aggregated,
85% of the study population were given BNT162b2)

BNT162b2,
ChAdOx1 nCoV-19,
mRNA-1273

Single dose: mRNA-1273 83% (95% CI 80–86); BNT162b2 66%
(64–68); ChAdOx1 64% (60–68) ≥14 days after the first dose
Double dose: mRNA-1273: 92% (86–96); BNT162b2: 89% (86–91)
≥7 days after the second dose. Insufficient data for ChAdOx1

√

√

X

√

X

+ NVX-CoV2373
(Novavax), ChAdOx1 nCoV-19 (AZD1222/Oxford–AstraZeneca), BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna) * Estimated efficacy due to the variant being dominant at the time of
√
study. indicates the study has been peer reviewed and X indicates the study has not been peer reviewed.
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Table 3. Vaccine Effectiveness against Beta (B.1.351) and Gamma (P.1) Variants.
Reference

Study Type

Population and Period

Location

Peer-Reviewed

Vaccine +

Reported Vaccine Efficacy

[18]

Phase 2 and Phase 3 trials

N/A

South Africa

X

NVX-CoV2373

Against B.1.351: 60% (CI Not reported) *

[19]

Test negative case-control
study

Qatari resident. February-March, 2021

BNT162b2

Against B.1.351
Single dose: 16.9% (95% CI 10.4–23.0)
Double dose: 75.0% (70.5–78.9) ≥14 days after the
second dose

[20]

Test negative case-control
study

104, 884 PCR-confirmed and negative for
B.1.351 Qatari residents. 28 December
2020–10 May 2021

Qatar

mRNA-1273

Against B.1.351
Single dose: 61.3% (95% CI 56.5–65.5) ≥14 days after the first
dose
Double dose: 96.4% (91.9–98.7) ≥14 days after the
second dose

[32]

Case-control study
(Questionnaire-based)

41,151 questionnaire respondants and
3644 controls. 14 February–3 May 2021

France

BNT162b2, mRNA-1273

Reported efficacies against both B.1.351 and P.1 combined:
Double dose: 77% (95% CI 63–86) 7 days after the second
dose. Reported efficacy for both mRNA vaccines aggregated

BNT162b2, mRNA-1273

Reported efficacies against both B.1.351 and P.1 combined:
Single dose: 43% (95% CI 22–59) ≥14 days after the first dose
Double dose: 88% (61–96) ≥7 days after the second dose (for
both vaccines aggregated)
Double dose against all variants combined: BNT162b2: 91%
(88–93), mRNA-1273: 94% (86–97)

BNT162b2, mRNA-1273

Results aggregated against all variants *:
Compared with community infection rates (for both vaccines
aggregated): Single dose: 54.7% (95% CI 44.8–62.9); Double
dose: 84.8% (75.2–90.7)

BNT162b2, mRNA-1273

Against P.1
Single dose: 61% (95% CI 45–72) (for both vaccines
aggregated, 85% of study population were given BNT162b2)

BNT162b2, ChAdOx1
nCoV-19, mRNA-1273

Reported efficacies against both B.1.351 and P.1 combined:
Single dose: mRNA-1273: 77% (95%CI 63–86); BNT162b2:
60% (52–67); ChAdOx1: 48% (28–63) ≥14 days after the
first dose
Double dose: BNT162b2: 84% (69–92) ≥7 days after the
second dose; Insufficient data for
ChAdOx1 and mRNA-1273

Qatar

Test negative case-control
study

324,033 residents aged ≥16. 14
December 2020–19 April 2021

[34]

Observational study

25, 558 health care workers aged 20–69.
15 March 2020–13 May 2021

Canada

[35]

Test negative case-control
study

16, 993 participants aged ≥70. 4 April–1
May 2021

Canada

[33]

[36]

Test negative case-control
study

682,071 symptomatic individuals aged
≥16. December 2020–March 2021

Canada

Canada

√

√

√

√

X

√

X
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Table 3. Cont.
Reference

Study Type

Population and Period

[37]

Phase 2a-b Randomized,
observer-blinded,
placebo-controlled trial

6324 participants, aged 18–84 without
HIV and 18–64 with HIV. 17 August –25
November 2020

South Africa

[38]

Phase 3 randomized,
double-blind,
placebo-controlled trial

6576 participants from South Africa aged
≥18. 21 September 2020–22 January 2021

South Africa

[39]

Randomized,
placebo-controlled,
observer-blind Phase 1/2/3
study

44,165 aged ≥16 and 2264 aged 12–15.
27 July–29 October 2020

South Africa

[40]

Test negative case-control
study

43,774 residents aged ≥70. 17
January–29 April 2021

Location

Brazil

[41]

Test negative case-control
study

106,329 health care workers aged ≥18.
19 January–25 March 2021

[42]

Double-blind, randomized,
controlled trial

2026 HIV-negative adults aged 18–64. 24
June–9 November 2020

South Africa

[43]

Retrospective cohort study

378 residents from long-term care
facilities. 15 January–19 May 2021

France

Brazil

Peer-Reviewed

√

√

X

√

X

√

X

Vaccine +

Reported Vaccine Efficacy

NVX-CoV2373

Overall efficacy against B.1.351: 49.4% (95% CI 6.1–72.8)
Post hoc vaccine efficacy against B.1.351: 51.0% (−0.6–76.2)
among HIV-negative participants

Ad26.COV2.S

Against B.1.351 (Represented 95% of cases)
Single dose: 52.0% (95% CI 30.3–67.4) ≥14 days after the first
dose increasing to 64.0% (41.2–78.7) ≥28 days after the
first dose

BNT162b2

Against B.1.351: 100% (95% CI 53.5–100.0) * >7 days after the
second dose

CoronaVac

Against P.1 *
Single dose: 12.5% (95% CI 3.7–20.6) ≥14 days after the
first dose
Double dose: 46.8% (38.7–53.8) ≥14 days after the
second dose

CoronaVac

Against P.1 *
Single dose: 49.6% (95% CI 11.3–71.4) ≥14 days after the first
dose
Double dose: 36.8% (-54.9–74.2) ≥14 days after the second
dose

ChAdOx1 nCoV-19

Overall efficacy against B.1.351: 21.9% (95% CI −49.9–59.8)
>14 days after second dose
Secondary-outcome analysis efficacy against B.1.351: 10.4%
(−76.8–54.8) >14 days after the second dose

BNT162b2

Against B.1.351 infection: 49% (95% CI 14–69) >7 days after
the second dose
Against B.1.351 severe COVID: 86% (67–94) >7 days after the
second dose

+ NVX-CoV2373 (Novavax), Ad26.COV2.S (Johnson
√ & Johnson/Janssen), ChAdOx1 nCoV-19 (AZD1222/Oxford–AstraZeneca), BNT162b2 (Pfizer–BioNTech), mRNA-1273 (Moderna). * Estimated efficacy due to
the variant being dominant at the time of study. indicates the study has been peer reviewed and X indicates the study has not been peer reviewed.

Vaccines 2021, 9, 1305

10 of 18

Several phases 1–3 clinical trials reported efficacies against the Beta (B.1.351) variant ([18,37–39]). The lowest efficacy reported is 49.4% with at least one dose of NVX-CoV2373 [37]
and the highest efficacy is 100% for two doses of BNT162b2 [39]. The NVX-CoV2373
Phase 2A,B randomized, observer-blinded controlled trial was conducted in South Africa
between 17 August and 25 November 2020 [37]. The overall vaccine efficacy was 49.4%
but was slightly higher at 51.0% in HIV-negative participants. No serious adverse effects
were reported as being related to the vaccine. E. Mahase [18] reported an efficacy of 60%
for the NVX-CoV2373 trial against the B.1.351 variant. A Phase 3 randomized, doubleblind, placebo-controlled trial for a single dose of Ad26.COV2.S vaccine was conducted
in several countries including US, Brazil, and South Africa [38]. The trial period was
between 21 September 2020, and 22 January 2021. The study included 4969 participants
from South Africa, where the B.1.351 variant was dominant. The vaccine efficacy from the
South Africa group was 52.0% for moderate to severe-critical COVID-19 after 14 days of
administration and increased to 64.0% after 28 days. Serious adverse effects not related to
COVID-19 were only reported by 83 out of 21,895 vaccine recipients constituting 0.4% of
the population and 96 out of 21,888 placebo recipients constituting 0.4% of the population.
A Phase 2 observer-blinded controlled trial for BNT162b2 was conducted between July
and October 2020 and included 45,411 participants aged 16 or older from US, Argentina,
Brazil, South Africa, Germany, and Turkey [39]. Although a 91% overall efficacy was
reported, the efficacy specifically for the South African group with predominantly B.1.351
variant in circulation was reported to be 100%. The paper also reported new adverse events
attributed to the BNT162b2 vaccine not identified in earlier reports. These adverse events
decreased appetite, lethargy, asthenia, malaise, night sweats, and hyperhidrosis. The study
however has not been peer-reviewed at the time of writing. Moreover, for fully vaccinated
individuals, 4 out of the 7 studies reported efficacies between 22 and 60%, and 3 reported
efficacies between 75 and 100%. Therefore, more data are needed for convincing evidence.
The efficacies reported against Gamma (P.1) variant is all from observational studies.
Three of the involved studies reported efficacies for the P.1 variant exclusively ([35,40,41]).
Protection against this variant is indicated to be lower ranging from 12.5% for a single
dose of CoronaVac [40] and 61% for a single dose of mRNA vaccine (BNT162b2 and
mRNA-1273) [35]. Both studies on the CoronaVac vaccine against the P.1 variant were conducted in Brazil ([40,41]). The test negative case-control study [40] included 43,744 adults
aged 70 years or older between 17 January and 29 April 2021. For two doses of CoronaVac,
the vaccine efficacy against COVID-19 infection was only at 46.8%. However, the adjusted
effectiveness against COVID-19 hospital admissions and deaths was 55% and 61.2% respectively. The study by M. D. T. Hitchings et al. [41] meanwhile included 106,329 healthcare
workers aged 18 years or older between 19 January and 25 March 2021. The adjusted vaccine effectiveness was 49.6% after the first dose of CoronaVac. However, the effectiveness
reported after two doses was unusually lower at 36.8%. This study was not peer-reviewed
at the time of writing. Overall, the limited data available against the P.1 variant indicates
lower protectiveness. The highest efficacy was only 61% with a single dose of mRNA
vaccine but can be expected to be higher with full vaccination.
For studies reporting efficacies of both B.1.351 and P.1 variants together ([32,33,36]), the
reported efficacies for double dose mRNA vaccines are 84%, 88%, and 77% respectively. The
high efficacies against both variants combined seem to indicate slightly greater protection
against B.1.351 compared to P.1. This conclusion can be drawn solely based on the efficacy
results available exclusively against the two variants where the range of efficacy against
the B.1.351 variant was between 22% and 100% and the range of efficacy against the P.1
variant was between 12.5% and 61%.
3.3. Vaccine Protection against Delta (B.1.617.2) SARS-CoV-2 Variant
Among the variants considered, the Delta (B.1.617.2) variant is the latest to be designated as a VOC. Consequently, only 30% of the research reporting vaccine efficacies against
this variant is from peer-reviewed literature and no data from a clinical trial is available
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at the time of writing. The studies reporting vaccine effectiveness against the B.1.617.2
variant are summarized in Table 4.
Several studies have indicated a drop in protection against the Delta variant. Vaccine efficacy for Mesa County, Colorado was reported to be 78% with Delta being the
prevalent variant [44]. In contrast, for the same period of time, efficacy from the other
Colorado counties was 89% where the Delta variant was comparatively lower. Similarly,
S. Y. Tartof et al. [45] indicated lower protection against Delta (75% efficacy) compared to
other variants (91% efficacy). A sharp decline in vaccine effectiveness is reported after
the Delta variant became prevalent with the effectiveness reducing from 91% to 66% [46].
This is also indicated by A. Puranik et al. [22] where a sharp decline in efficacy is observed from July 2021 when the Delta variant replaced the Alpha variant as the dominant
variant (Figure 3).
Moreover, among the two mRNA vaccines, several studies indicate slightly higher
protection from the Moderna (mRNA-1273) vaccine compared to the Pfizer (BNT162b2)
vaccine. For both single and double doses, mRNA-1273 (79% and 84.8%) offered greater
protection than BNT162b2 (64.2% and 53.5%) against the Delta variant [47]. Similarly, for
two doses of either, mRNA-1273 (76%) was reported to be more effective than BNT162b2
(42%) [22]. For a single dose of mRNA vaccine, a higher efficacy for mRNA-1273 (72%)
than BNT162b2 (56%) is reported against the Delta variant [36].
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Table 4. Vaccine Effectiveness Against Delta (B.1.617.2) Variant.
Reference

Study Type

Population and Period

Location

Peer-Reviewed

Vaccine +

Reported Vaccine Efficacy

[21]

Test negative case-control
study

19,109 participants aged ≥16. 26 October
2020–30 May 2021

√

BNT162b2, ChAdOx1
nCoV-19

BNT162b2 and ChAdOx1 Single dose:
30.7% (95% CI, 25.2–35.7)
BNT162b2 Double dose: 88.0% (85.3–90.1)
ChAdOx1 nCoV-19 Double dose: 67.0% (61.3–71.8)

[22]

Test negative case-control
study

25,589 participants aged ≥18.
January–July 2021

X

BNT162b2, mRNA-1273

Results aggregated against all variants *:
mRNA-1273: 86% (95% CI 81–90.6); BNT162b2: 76% (69–81)
≥14 days after the second dose.
During July 2021 (high prevalence of B.1.617.2): mRNA-1273:
76% (58–87); BNT162b2: 42% (13–62)

US

[36]

Test negative case-control
study

682,071 symptomatic individuals aged
≥16. December 2020–March 2021

Canada

X

BNT162b2, ChAdOx1
nCoV-19, mRNA-1273

Single dose: mRNA-1273: 72% (95% CI 57–82); BNT162b2:
56% (45–64); ChAdOx1: 67% (44–80) ≥14 days after first dose
Double dose: BNT162b2: 87% (64–95) ≥7 days after the
second dose; Insufficient data for ChAdOx1 and mRNA-1273

[44]

Observational Study

1945 reported cases.
27 April–6 June 2021

US

√

BNT162b2, mRNA-1273,
Ad26.COV2.S

Against symptomatic infection for 2 weeks: 78% (95% CI
71–84) * for Mesa County (most cases were B.1.617.2),
aggregated for all vaccines

[45]

Retrospective cohort study

3,436,957 participants aged ≥12.
14 December 2020–8 August 2021

US

X

BNT162b2

Against B.1.617.2: 75% (95% CI 71-78) double dose
Against other variants: 91% (88-92) double dose

[46]

Prospective cohort study

4217 participants.
14 December 2020–14 August 2021

US

X

BNT162b2, mRNA-1273

B.1.617.2 predominant period: 66% (95% CI 26–84) *
Before B.1.617.2 predominant period: 91% (81–96)
For fully vaccinated participants, aggregated for both
vaccines

BNT162b2, mRNA-1273

BNT162b2 Single dose: 64.2% (95% CI 38.1–80.1)
BNT162b2 Double dose: 53.5% (43.9–61.4)
mRNA-1273 Single dose: 79.0% (58.9–90.1)
mRNA-1273 Double dose: 84.8% (75.9–90.8)
≥14 days after first dose and ≥14 days after second dose,
respectively

CoronaVac, CNB

Double dose: 59.0% (95% CI 16.0–81.6) Results aggregated for
all vaccines

UK

[47]

Test negative case-control
study

1,140,337 PCR-confirmed with Delta and
PCR-negative Qatari residents.
23 March–21 July 2021

Qatar

[48]

Test negative case-control
study

366 participants aged 18–59.
18 May–20 June 2021

China

[49]

Test negative case-control
study

5143 participants. 1 April–31 May 2021

India

X

ChAdOx1 nCoV-19

Overall: 63.1% (95% CI 51.5–72.1)
Only single dose: 46.2% (31.6–57.7)

[50]

Observational study

Population not specified.
16 January–28 June 2021

US

X

BNT162b2, mRNA-1273,
Ad26.COV2.S

Estimated against B.1.617.2: 82% (95% CI 78–85) *

X

√

+ CNB (China National Biotec inactivated vaccine), BNT162b2 (Pfizer–BioNTech),
mRNA-1273 (Moderna), Ad26.COV2.S (Johnson & Johnson/Janssen), ChAdOx1 nCoV-19 (AZD1222/Oxford–AstraZeneca).
√
* Estimated efficacy due to the variant being dominant at the time of study. indicates the study has been peer reviewed and X indicates the study has not been peer reviewed.
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et al. [45] indicated lower protection against Delta (75% efficacy) compared to other variants (91% efficacy). A sharp decline in vaccine effectiveness is reported after the Delta
variant became prevalent with the effectiveness reducing from 91% to 66% [46]. This is
also indicated by A. Puranik et al. [22] where a sharp decline in efficacy is observed from
13 of
18
July 2021 when the Delta variant replaced the Alpha variant as the dominant variant
(Figure 3).

Figure 3. Decrease in Vaccine Efficacy Against Delta (B.1.617.2) Variant [22].

4. Discussion
The effectiveness of COVID-19 vaccines against the new variants was highlighted and
compared in the previous sections. Given that vaccine effectiveness of higher than 50%
could substantially reduce incidence of COVID-19 in vaccinated individuals [8], the existing
vaccines from the available data indicates a good level of protection against the newer
variants, especially with two doses. The efficacy against the Alpha variant is reported to
be the highest, followed by Beta and Gamma variants. However, from the limited data
available, the efficacy against Delta variant is indicated to be lower but still effective. Based
on the studies, relevant discussions and comparison is presented hereafter.
4.1. Protection against COVID-19 Reference Variant and New Variants
Lower vaccine effectiveness against the newer variants is expected given the mutation.
NVX-CoV2373 [18] vaccine was found to be 95.6% effective against the reference variant
compared to only 85.6% and 60% for Alpha and Beta variants, respectively. Similarly, a drop
in efficacy against an Alpha variant of 86.3% compared to 96.4% against non-Alpha variants,
the majority of which was the reference variant was observed [16]. An observational study
from France indicated slightly lower protection for Alpha (86%) and Beta/Gamma (77%)
compared to the reference variant (88%) [32]. Therefore, data from the studies that have
reported efficacies both against the new variants as well as the original reference variant
confirms the decrease in efficacy with the emergence of variants. This decrease in efficacy
is consistent with the influenza virus analyzed data where a reduction in vaccine efficacy
against an emerging variant was reported in [51], with the effectiveness for influenza
A/H1N1 of 65% being reduced to 39% for the circulating A/H3N2 variant.
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4.2. Protection for Older Population against SARS-CoV-2 Variants
The effectiveness of vaccines in older aged population always remains a significant
point of discussion. The development of immunologic memory declines with age for
primary and booster vaccination [52]. Due to aging, a reduction in naive T cells that
respond to a vaccine is observed, with a significant decrease in CD8 T cells. Impaired CD8
T-cell effector responses and reduced CD4 T-cell functionality contributes to lower vaccine
response in older population. An earlier study on COVID-19 vaccines in older population
reported concern over limited trial data available for this age group [53]. Therefore,
research works that have reported vaccine efficacies against the newer variants with an
exclusively older age population in their studies are presented next. In a test negative
case-control study [25] during Alpha variant prevalence, both BNT162b2 and ChAdOx1
nCoV-19 vaccines were found to be effective. More significantly, a single dose of either
vaccine was found to be around 80% effective in preventing COVID-19-related hospital
admissions for the older population. The effectiveness of one dose mRNA vaccine among
the older population was investigated by D. M. Skowronski et al. [35]. The efficacies after
the first dose were 65% overall, 67% against Alpha, and 61% against Gamma for both
mRNA vaccines aggregated. Moreover, adults aged 70 or older from Brazil participated
in a test negative case-control study where the efficacy of the CoronaVac vaccine was
55.5% against COVID-19 hospital admissions and 61.2% against COVID-19 deaths against
the Gamma variant [40]. Similarly, the test negative case-control study [31] involved
participants aged 65 or older across Europe during predominantly Alpha variant period in
which for fully vaccinated BNT162b2 individuals, the protection against Alpha was high
(87%) and for one dose of ChAdOx1 nCoV-19 the protection was reasonable (68%). Finally,
a prospective cohort study involving care home residents aged 65 or older in England was
conducted during the prevalence of Alpha variant [29]. The reported effectiveness was 56%
(28 to 34 days) and 62% (35 to 48 days) after a single dose of ChAdOx1 or BNT162b2.
Therefore, from the studies that exclusively targeted an older population, the vaccines
appear to offer reasonable protection against the variants especially against severe illness
and deaths.
4.3. Protection against Other SARS-CoV-2 Variants
Besides the four major VOCs considered in this review, an observational study [23]
reported vaccine protection against the B.1.526 (Iota) variant. The study looked at 76 breakthrough cases of individuals who received full vaccination of BNT162b2, mRNA-1273, and
Ad26.COV2.S between February and April 2021. Although statistical analysis concluded an
effective level of protection against B.1.526, the study did not quantify the vaccine efficacy.
The efficacy against non-VOC was found to be higher (72%) compared to the Alpha (67%)
and Gamma (61%) VOCs [35]. However, the exact variants present in the non-VOC group
was not reported. Overall, from the existing works in the literature, only limited data are
available against other variants and non-VOCs in particular. However, it must be noted
that this is most likely due to the dominance of the four discussed variants in the current
study period.
4.4. Significance and Implication of This Review
This systematic review looked at existing research and compared the efficacies of
vaccines against SARS-CoV 2 variants. Concerns over the vaccine efficacies against the new
variants have been emphasized [54]. However, our study demonstrates that the vaccines
still provide strong protection against the variants especially in terms of severe illness and
hospitalization. Moreover, we are hopeful that our study will support the efforts to increase
vaccine acceptance with two doses for vulnerable people including the elderly population
and those with comorbidities especially against the Alpha and Beta variants.
This review provides a compressive and comparative study on vaccine efficacies
against various variants of COVID-19 and there are several key implications of this review.
First, it helps in increasing public health awareness among the population and addresses
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their concerns regarding the efficacies of the vaccines against new variants. Moreover, by
comparing the differences in efficacies between the various vaccines will help in prioritizing
further developments of these vaccines and help public decision making. Furthermore,
this type of comparative and comprehensive review assimilating the latest research supports policy makers, governments, and public health community in assessing the stability,
sustainability, and resilience of vaccines against emerging variants.
However, there remains some unanswered research questions regarding the efficacies
of vaccines against the variants which will lead to the development of future research
direction. First, it is still not evident what the best approach is in designing a vaccine that
can be tested against and unknown or non-prevalent variant. Researchers should also
investigate the possibility of predicting emerging variants and the best vaccine design for
protection against these variants. Moreover, design and development of a safe and effective
vaccine that can offer strong protection against all existing variants and future mutations
should be examined. Recent studies have also indicated that booster vaccinations can be
a useful long-term global health strategy if the existing vaccines cannot offer significant
protection against emerging variants [55]. Therefore, researchers are encouraged to examine
existing vaccine efficacy data from booster vaccines against the variants.
4.5. Strengths and Limitations of This Review
The systematic review to the best of our knowledge is the first one addressing the
efficacies of vaccines against the SARS-CoV-2 variants. The search strategies and inclusion
criteria used was clearly defined and PRISMA recommendations for systematic reviews
were followed. Additionally, risk of bias assessment was performed to assess the included research articles. Although most of the included articles were peer-reviewed, many
preprints were also included. Preprints were useful for obtaining the most recent results
due to the topic being part of a very active area of research. Furthermore, in light of
the COVID-19 pandemic, preprints now offer an unprecedented level of research significance [56] and therefore their usage is appropriate.
This review also has some limitations. First, meta-analysis was not performed in this
work and the lack of statistical analysis can be considered a weakness. Moreover, different
approaches to vaccine efficacy calculation and estimation were used in the included studies
and in this review the results were presented without adjusting for the different methods.
Finally, Medline and Embase databases were not used leading to a possibility of missing a
small number of published studies.
5. Conclusions
Studies of vaccine’s effectiveness have been considered a key factor for any vaccine’s
evaluation to ensure higher degree of protection. These studies are more relevant for
viruses that continuously mutate to new variants were vaccine’s efficacities might decline
with new derivations of the virus. Various research has been conducted to access the
COVID-19 vaccine’s efficacies. However, no comprehensive study has been conducted to
assess and compare efficiency of vaccines with various variants of COVID-19.
This systematic review compared the vaccine efficacies of COVID-19 vaccines against
the newer variants. A total of 35 research articles were included in the review and included
test negative case-control studies, Phase 1–3 clinical trial results, and observational studies.
Results indicate that although efficacy is lower than the reference strain, the vaccines offer
a good level of protection against the newer variants, especially with two doses. Protection
against the Alpha variant is highest, followed by Beta and Gamma variants. Efficacy seems
to be lower for the Delta variant from the limited data available. Results also indicate a
good level of protection for the older population aged 60 or older. However, not enough
data are available for other variants besides Alpha, Beta, Gamma, and Delta.
Supplementary Materials: The following are available online at https://www.mdpi.com/article/10
.3390/vaccines9111305/s1, File S1: ROB Quality Assessment.
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